IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update

3 Agenda IDE397 Interim Phase 1 Clinical Data Update GSK Option Data Package and Collaboration Economics. Phase 1/2 Clinical Development Plan Clinical Pharmacokinetic Data ■ Clinical Adverse Events IDE397 Pharmacodynamic Data Preclinical Tumor Pharmacodynamic Data . . Clinical Plasma and Tumor Pharmacodynamic Data ● PK/PD Analysis and Projected Clinical Efficacy Next Steps Corporate Update Other Pipeline Programs, 2022 Target Milestones, 2021 Financials gsk IDEA A IDEAVA BIOSCIENCES

View entire presentation